| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christian Oefner, Sabine Pierau, Henk Schulz, Glenn E Dal. Structural studies of a bifunctional inhibitor of neprilysin and DPP-IV. Acta crystallographica. Section D, Biological crystallography. vol 63. issue Pt 9. 2007-10-18. PMID:17704566. |
neutral endopeptidase (nep) is the major enzyme involved in the metabolic inactivation of a number of bioactive peptides including the enkephalins, substance p, endothelin, bradykinin and atrial natriuretic factor, as well as the incretin hormone glucagon-like peptide 1 (glp-1), which is a potent stimulator of insulin secretion. |
2007-10-18 |
2023-08-12 |
human |
| Patricia L Brubake. Incretin-based therapies: mimetics versus protease inhibitors. Trends in endocrinology and metabolism: TEM. vol 18. issue 6. 2007-10-12. PMID:17629492. |
the physiological incretins, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), lower blood glucose levels through multiple mechanisms, including enhancement of glucose-stimulated insulin secretion. |
2007-10-12 |
2023-08-12 |
Not clear |
| Alissa K Langley, Terri J Suffoletta, Heath R Jenning. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy. vol 27. issue 8. 2007-10-11. PMID:17655515. |
unlike conventional oral antidiabetic agents, these agents promote glucose homeostasis through inhibition of dpp-iv, the enzyme responsible for degradation of two key glucoregulatory hormones: glucagon-like peptide-1 (glp-1), which extends the action of insulin while also suppressing the release of glucagon, and glucose-dependent insulinotropic peptide (gip). |
2007-10-11 |
2023-08-12 |
Not clear |
| George G Sokos, Hakki Bolukoglu, Judy German, Teresa Hentosz, George J Magovern, Thomas D Maher, David A Dean, Stephen H Bailey, Gary Marrone, Daniel H Benckart, Dariush Elahi, Richard P Shanno. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. The American journal of cardiology. vol 100. issue 5. 2007-10-11. PMID:17719327. |
glp-1 resulted in better glycemic control in the pre- and perioperative periods (glp-1 95 +/- 3 mg/dl, control 140 +/- 10 mg/dl, p insulin requirements to achieve the same glycemic control in the postoperative period (glp-1 139 +/- 4 mg/dl, control 140 +/- 3 mg/dl). |
2007-10-11 |
2023-08-12 |
Not clear |
| George G Sokos, Hakki Bolukoglu, Judy German, Teresa Hentosz, George J Magovern, Thomas D Maher, David A Dean, Stephen H Bailey, Gary Marrone, Daniel H Benckart, Dariush Elahi, Richard P Shanno. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. The American journal of cardiology. vol 100. issue 5. 2007-10-11. PMID:17719327. |
in conclusion, the perioperative use of glp-1 achieves better glycemic control and comparable hemodynamic recovery without the requirements for high-dose insulin or inotropes. |
2007-10-11 |
2023-08-12 |
Not clear |
| N Soltani, M Kumar, Y Glinka, G J Prud'homme, Q Wan. In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene therapy. vol 14. issue 12. 2007-09-27. PMID:17410180. |
treatment with glp-1/igg-fc or ex4/igg-fc improved glucose tolerance and increased circulating insulin and glp-1 levels. |
2007-09-27 |
2023-08-12 |
mouse |
| M Puig-Domingo, J Revirieg. [Incretins as new therapeutic targets of type 2 diabetes]. Revista clinica espanola. vol 207. issue 7. 2007-09-18. PMID:17662202. |
the incretin mimetics bind to glp-1 receptors, increasing glucose-dependent secretion of insulin and decreasing glucose-dependent posprandial secretion of glucagon, slowing gastric emptying, and reducing food intake. |
2007-09-18 |
2023-08-12 |
Not clear |
| Verónica Sancho, Bernardo Nuche, Luis Arnés, Jesús Cancelas, Nieves González, Mariano Díaz-Miguel, Antonio Martín-Duce, Isabel Valverde, María L Villanueva-Peñacarrill. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. International journal of molecular medicine. vol 19. issue 6. 2007-09-14. PMID:17487430. |
we investigated in normal human adipocytes the effect of glp-1, ex-4 and ex-9, compared with insulin upon the activity of pi3k, pkb, mapks and p70s6 kinases, and the participation of these enzymes in their action upon 2-deoxy-d-glucose transport by using potential inhibitors. |
2007-09-14 |
2023-08-12 |
human |
| Verónica Sancho, Bernardo Nuche, Luis Arnés, Jesús Cancelas, Nieves González, Mariano Díaz-Miguel, Antonio Martín-Duce, Isabel Valverde, María L Villanueva-Peñacarrill. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. International journal of molecular medicine. vol 19. issue 6. 2007-09-14. PMID:17487430. |
in normal subjects, glp-1, ex-4 and insulin, but not ex-9, increased glucose uptake. |
2007-09-14 |
2023-08-12 |
human |
| Verónica Sancho, Bernardo Nuche, Luis Arnés, Jesús Cancelas, Nieves González, Mariano Díaz-Miguel, Antonio Martín-Duce, Isabel Valverde, María L Villanueva-Peñacarrill. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. International journal of molecular medicine. vol 19. issue 6. 2007-09-14. PMID:17487430. |
in addition, glp-1 and ex-4 stimulated pi3k and mapks, similar to insulin, but not pkb. |
2007-09-14 |
2023-08-12 |
human |
| Verónica Sancho, Bernardo Nuche, Luis Arnés, Jesús Cancelas, Nieves González, Mariano Díaz-Miguel, Antonio Martín-Duce, Isabel Valverde, María L Villanueva-Peñacarrill. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. International journal of molecular medicine. vol 19. issue 6. 2007-09-14. PMID:17487430. |
inhibition of both pi3k and mapks blocked the stimulatory action of glp-1, ex-4 and insulin upon glucose transport. |
2007-09-14 |
2023-08-12 |
human |
| Verónica Sancho, Bernardo Nuche, Luis Arnés, Jesús Cancelas, Nieves González, Mariano Díaz-Miguel, Antonio Martín-Duce, Isabel Valverde, María L Villanueva-Peñacarrill. The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. International journal of molecular medicine. vol 19. issue 6. 2007-09-14. PMID:17487430. |
in obese patients, basal pi3k, pkb and mapk activity was, as a rule, lower than that in normal subjects, while cells maintained their normal incremental response to glp-1, ex-4 or insulin; ex-9 induced a clear stimulation of p42 mapk. |
2007-09-14 |
2023-08-12 |
human |
| S Wan, F H Coleman, R A Travagl. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. American journal of physiology. Gastrointestinal and liver physiology. vol 292. issue 6. 2007-08-30. PMID:17322063. |
glucagon-like peptide-1 (glp-1) increases pancreatic insulin secretion via a direct action on pancreatic beta-cells. |
2007-08-30 |
2023-08-12 |
Not clear |
| B Gallwit. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. International journal of clinical practice. vol 60. issue 12. 2007-08-23. PMID:17109672. |
the incretin hormone glucagon-like peptide-1 (glp-1) not only stimulates insulin secretion under hyperglycaemic conditions, but also suppresses glucagon secretion, slows gastric emptying, induces satiety and improves beta cell function in type 2 diabetes. |
2007-08-23 |
2023-08-12 |
Not clear |
| Raquel Ferrer-Lorente, Cristina Cabot, José-Antonio Fernández-López, Marià Aleman. Effects of combined oleoyl-estrone and rimonabant on overweight rats. Journal of pharmacological sciences. vol 104. issue 2. 2007-08-23. PMID:17558182. |
glycemia was maintained, but oe decreased insulin, glp-1, and cholesterol, whilst rimonabant increased cholecystokinin and cholesterol, and decreased nefa. |
2007-08-23 |
2023-08-12 |
rat |
| Subhasis Roy, Vivek Khanna, Shivani Mittra, Arti Dhar, Shuchita Singh, Dipak C Mahajan, Priyanka Priyadarsiny, Joseph A Davis, Jitendra Sattigeri, Kulvinder S Saini, Vinay S Bansa. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice. Life sciences. vol 81. issue 1. 2007-08-20. PMID:17532347. |
plasma active glucagon like peptide-1 (glp-1) and insulin levels were found to be elevated significantly (p<0.01 and p<0.05 respectively) in both laf-237 and combination treated groups following oral glucose load. |
2007-08-20 |
2023-08-12 |
mouse |
| J F Todd, S R Bloo. Incretins and other peptides in the treatment of diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 24. issue 3. 2007-08-13. PMID:17263764. |
glucagon-like peptide-1 (7-36) amide (glp-1) is a gut hormone, released postprandially,which stimulates insulin secretion and insulin gene expression as well as pancreatic b-cell growth. |
2007-08-13 |
2023-08-12 |
human |
| J F Todd, S R Bloo. Incretins and other peptides in the treatment of diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 24. issue 3. 2007-08-13. PMID:17263764. |
patients with type 2 diabetes have greatly impaired or absent incretin-mediated insulin secretion which is mainly as a result of decreased secretion of glp-1. |
2007-08-13 |
2023-08-12 |
human |
| J F Todd, S R Bloo. Incretins and other peptides in the treatment of diabetes. Diabetic medicine : a journal of the British Diabetic Association. vol 24. issue 3. 2007-08-13. PMID:17263764. |
in addition to stimulating insulin secretion and promoting pancreatic b-cell mass, glp-1 suppresses glucagon secretion,delays gastric emptying and inhibits food intake. |
2007-08-13 |
2023-08-12 |
human |
| Baptist Gallwit. New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. The review of diabetic studies : RDS. vol 2. issue 2. 2007-08-10. PMID:17491680. |
in humans, the improvement of beta-cell function can be indirectly observed from the increased insulin secretory capacity after glp-1 infusions. |
2007-08-10 |
2023-08-12 |
Not clear |